Arrowhead Pharmaceuticals

ARWR Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$61.03

-3% today

52W: $9.57 – $76.76

52W Low: $9.57 Position: 76.6% 52W High: $76.76

🔗 Compare Brokers

Key Metrics

P/E Ratio

38.14x

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

7.83x

Price-to-Sales

EV/EBITDA

25.56x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$8.5B

Market Capitalization

Revenue Growth

10461.3%

YoY Revenue Growth

Profit Margin

18.54%

Net profit margin

ROE

75.5%

Return on Equity

Beta

1.27

Market sensitivity

Short Interest

11.39%

% of float sold short

Avg. Volume

2,979,834

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

11 analysts

Avg. Price Target

$81.09

+32.87% upside

Target Range

$35.00 – $110.00

About the Company

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Ph

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 711 Exchange: NMS